Refractory Angina - Market Insights, Epidemiology and Market Forecast - 2030
発行: DelveInsight Business Research LLP
ページ情報: 英文 131 Pages
当レポートは、世界の難治性狭心症関連市場を調査したもので、市場の概要、 疫学と患者数、国別の状況、治療法、ケーススタディ、関連組織、主な地域市場の分 析などの情報を提供しています。
DelveInsight's 'Refractory Angina (RA) - Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of RA in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Refractory Angina (RA) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Study Period: 2017-2030
Refractory Angina (RA) is a chronic condition where pain remain persistent for the duration of less than or equal to 3 months, characterized by angina. Angina is a type of chest pain caused by reduced blood flow to the heart. Angina has two types, chronic or stable angina and unstable angina. Around 10-15% of patients of Chronic Angina meet the measures of RA. The clinical load of RA is growing rapidly due to an ageing population and improved Coronary Artery Disease (CAD).
The goal of medicine is to improve the patient's quantity and quality of life. In the case of coronary artery disease, disease-modifying treatments have proved to be beneficial. The mainstay of anginal pain treatment is still based on nitrates, beta-blockers, calcium antagonists (with the addition of ranolazine and ivabradine), and coronary revascularization. These treatments match myocardial O2 supply and demand through variable mechanisms: coronary flow reserve increase, heart rate reduction, myocardial inotropy modulation, and improvements in cellular metabolism. Despite the optimal combination of such therapeutics, a substantial proportion of stable CAD patients continues to experience disabling angina resulting in the impairment in quality of life of the patients constituting refractory angina pectoris (RAP) population.
The DelveInsight Refractory Angina (RA) market report gives the thorough understanding of the Refractory Angina by including details such as disease definition, classification, symptoms, etiology, pathophysiology, complications, biomarkers and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Refractory Angina in the US, Europe and Japan.
The Refractory Angina (RA) epidemiology division provides the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Population of Coronary Artery Disease and Refractory Angina, Sub-type Specific Prevalence, Gender-specific Prevalent Population of Refractory Angina and Diagnosed Population of NORDA) scenario of Refractory Angina (RA) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.
According to DelveInsight, the total number of prevalent cases of Refractory Angina (RA) in 7 MM was found to be 29,17,196 in the year 2017.
This segment of the Refractory Angina report encloses the detailed analysis of marketed drugs and early stage (Phase-I and Phase-II) pipeline drugs along with other promising candidates. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
A multidisciplinary treatment approach is usually followed internationally for the management of RA and the market consequently can be divided into segments based on revenue generated by therapies which include pain control, management of exocrine and endocrine insufficiency and management of other complications. However, there are important points to be noted such as the fact that there are not curative treatment options at present and all the therapies used are either off-label or symptomatic in nature.
The Refractory Angina market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Refractory Angina in 7MM was found to be USD 1387 Million in 2017, and is expected to increase during the course of the study period (2017-2030). Among the 7MM, the United States accounts for the largest market size of RA, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.